A Randomized, Double-Blind, Phase 3 Study of Pemrbolizumab/Vibostolimab (MK-7684A) in combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants with Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
Adult
- Stage IV squamous or nonsquamous NSCLC - Confirmation that EGFR-, ALK-, or ROS1-directed therapy is not indicated as primary therapy - Has not received prior systemic treatment for metastatic NSCLC - Greater than or equal to 18 years of age - ECOG PS of 0 or 1 assessed within 7 days before randomization - Has a life expectancy of at least 3 months
Treatment
Greeley Campus
Harmony Campus
Medical Center of the Rockies
Poudre Valley Hospital
Steven Schuster, MD
Protocol Number: 22-0577
More information available at ClinicalTrials.gov: NCT05226598
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers